Soligenix, Inc. (SNGX)
SNGX moved a median of -0.71% 30 minutes after news, and -1.75% by the close. How SNGX actually reacts to news — the realized, point-in-time move the market made, measured across 251 labeled events over the last three years with zero look-ahead.
SNGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 34% | 240 |
| 30-min | -0.71% | 35% | 246 |
| 60-min | -1.29% | 35% | 246 |
| to close | -1.75% | 34% | 241 |
| Middle 50% of SNGX reactions | -2.54% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.71% |
| Measured reactions | 251 |
Half of all Soligenix, Inc. news events land between -2.54% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SNGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SNGX's baseline. Nothing else.
Recent SNGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K SOLIGENIX, INC. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | -0.10% | |
| Form 10-Q SOLIGENIX, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.00% | — | |
| Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | Press release | PR Newswire | +2.63% | +3.18% | |
| Form ARS SOLIGENIX, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.13% | -0.16% | |
| Form DEF 14A SOLIGENIX, INC. For: Sep 17 | SEC filing · Form DEF | SEC EDGAR | -0.13% | -0.16% | |
| Form DEFA14A SOLIGENIX, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.13% | -0.16% | |
| Form PRER14A SOLIGENIX, INC. | SEC filing · Form PRER14A | SEC EDGAR | -2.67% | +0.35% | |
| Form PRE 14A SOLIGENIX, INC. For: Sep 17 | SEC filing · Form PRE | SEC EDGAR | +0.80% | -0.41% | |
| Form 8-K SOLIGENIX, INC. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -2.44% | |
| Form 8-K SOLIGENIX, INC. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | +4.63% | |
| Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | Press release | PR Newswire | -3.08% | -5.71% | |
| Form 8-K SOLIGENIX, INC. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -3.35% | +0.00% | |
| Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo | Press release | PR Newswire | -0.03% | +28.54% | |
| Form 10-Q SOLIGENIX, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.41% | -3.41% | |
| Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | Press release | PR Newswire | -4.54% | -11.21% | |
| Form 8-K SOLIGENIX, INC. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -10.51% | -31.07% | |
| Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma | Press release | PR Newswire | -10.51% | -31.07% | |
| Form EFFECT SOLIGENIX, INC. | SEC filing · Form EFFECT | SEC EDGAR | -2.59% | -1.72% | |
| Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy | Press release | PR Newswire | -2.65% | +0.89% | |
| Form 10-K SOLIGENIX, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.53% | -4.96% | |
| Form POS AM SOLIGENIX, INC. | SEC filing · Form POS | SEC EDGAR | +0.53% | -4.96% | |
| Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results | Press release | PR Newswire | +0.00% | +8.26% | |
| Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease | Press release | PR Newswire | -6.97% | -0.82% | |
| HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 | Press release | PR Newswire | +0.00% | +1.68% | |
| IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. | Press release | GlobeNewswire | +0.00% | +1.67% | |
| Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" | Press release | PR Newswire | +0.00% | +1.67% | |
| Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency | Press release | PR Newswire | +0.85% | +5.13% | |
| Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease | Press release | PR Newswire | +3.45% | -0.86% | |
| Soligenix to Present at BIO Investment & Growth Summit | Press release | PR Newswire | +0.00% | +5.50% | |
| Form 8-K SOLIGENIX, INC. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +3.81% | +3.81% | |
| Soligenix Details Recent Progress and Upcoming Milestones | Press release | PR Newswire | +0.00% | -2.75% | |
| Form 8-K SOLIGENIX, INC. For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -4.44% | |
| Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Press release | PR Newswire | -3.86% | -7.52% | |
| Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis | Press release | PR Newswire | -0.71% | -12.14% | |
| Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad | Press release | GlobeNewswire | -3.28% | -1.83% | |
| Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space | Press release | GlobeNewswire | -1.91% | -1.27% | |
| Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma | Press release | PR Newswire | +0.66% | -5.71% | |
| Form 8-K SOLIGENIX, INC. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -5.71% | |
| Form 10-Q SOLIGENIX, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.70% | -4.22% | |
| Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results | Press release | PR Newswire | -2.33% | +6.20% | |
| Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma | Press release | PR Newswire | -1.76% | -4.12% | |
| Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma | Press release | PR Newswire | -0.32% | +5.13% | |
| Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma | Press release | PR Newswire | +3.60% | +4.50% | |
| Form 8-K SOLIGENIX, INC. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +3.60% | +4.50% | |
| Soligenix Announces Closing of $7.5 Million Public Offering | Press release | PR Newswire | +3.60% | +4.50% | |
| Form EFFECT SOLIGENIX, INC. | SEC filing · Form EFFECT | SEC EDGAR | +5.04% | +0.84% | |
| Soligenix Announces Pricing of $7.5 Million Public Offering | Press release | PR Newswire | +5.04% | +0.84% | |
| Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor | Press release | PR Newswire | -1.08% | -10.14% | |
| Form S-1 SOLIGENIX, INC. | SEC filing · Form S-1 | SEC EDGAR | -0.39% | -8.63% | |
| Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses | Press release | PR Newswire | -0.69% | +4.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SNGX section they belong to.
Where else SNGX is measured.
SNGX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
| Mersana Therapeutics, Inc. (MRSN) | 251 | -0.20% | 46% |
| Co-Diagnostics, Inc. (CODX) | 250 | 0.00% | 46% |
| argenx SE - American Depositary Shares (ARGX) | 249 | -0.02% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Soligenix, Inc.'s median reaction calculated?
Every labeled SNGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 251 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of SNGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SNGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.